<DOC>
	<DOCNO>NCT00104741</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Drugs , triptorelin flutamide , may stop adrenal gland make androgen . Radiation therapy use high-energy x-ray kill tumor cell . Giving triptorelin flutamide together radiation therapy may effective treatment prostate cancer . It yet know whether give triptorelin flutamide together external-beam radiation therapy effective external-beam radiation therapy alone treat prostate cancer . PURPOSE : This randomized phase III trial study triptorelin , flutamide , external-beam radiation therapy see well work compare external-beam radiation therapy alone treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Triptorelin , Flutamide , External-Beam Radiation Therapy External-Beam Radiation Therapy Alone Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare impact neoadjuvant androgen blockade therapy comprise triptorelin flutamide follow conformal external beam radiotherapy continue androgen blockage therapy v conformal external beam radiotherapy alone patient stage II III prostate cancer . - Compare survival rate , term 5-year clinical biological remission , patient treat regimen . - Compare overall survival patient treat regimen . - Compare acute late toxicity regimens patient . - Compare quality life patient treat regimen . - Determine value time-delay obtain prostate-specific antigen nadir patient treat external beam radiotherapy alone . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo conformal external beam radiotherapy . - Arm II : Patients receive androgen blockade therapy comprise triptorelin subcutaneously every 4 week oral flutamide daily . Androgen blockade therapy continue total 4 month . Two month initiation androgen blockade therapy , patient undergo conformal external beam radiotherapy . Quality life assess . PROJECTED ACCRUAL : A total 450 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer , meet follow clinical stag criterion : Stage T1bT1c AND prostate specific antigen ( PSA ) ≥ 10 ng/mL OR Stage T1bT1c AND Gleason score ≥ 7 OR Stage T2aT3a No lymph node invasion ( N0 N ) Patients ≥ 10 % risk Partin table must undergo curage No metastatic disease ( M0 ) thoracic radiography bone scan PSA &lt; 30 ng/mL No history invasive cancer PATIENT CHARACTERISTICS : Age Under 75 Performance status ECOG 01 Life expectancy At least 10 year Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No prior hormonal therapy Radiotherapy No prior pelvic radiotherapy Surgery No prior radical prostatectomy No prior castration</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>